Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 10 2020
09 10 2020
Historique:
received:
06
10
2019
accepted:
17
08
2020
entrez:
10
10
2020
pubmed:
11
10
2020
medline:
9
3
2021
Statut:
epublish
Résumé
Accumulating evidence indicates that persistent Helicobacter pylori gastric infection influences immune responses to oral enteric vaccines. We studied the association between pre-existing H. pylori serum IgG and serum pepsinogens levels (PGs) as markers of gastric inflammation and the immune response to single-dose live oral cholera vaccine CVD 103-HgR in Malian adults. Baseline sera obtained during a phase 2 safety/immunogenicity clinical trial of cholera vaccine CVD 103-HgR among 93 healthy Malian adults were tested for H. pylori IgG antibodies and PGI and PGII levels using enzyme linked immunosorbent assays. Overall 74/93 (80%) vaccine recipients were H. pylori IgG seropositive at baseline. Vibriocidal antibody seroconversion (≥ fourfold increase 14 days following administration of CVD 103-HgR compared to baseline) among vaccine recipients was 56%. However, vibriocidal antibody seroconversion was markedly higher among H. pylori seropositives than seronegatives 64% vs. 26% (p = 0.004); adjusted relative risk: 2.20 (95% confidence intervals 1.00-4.80; p = 0.049). Among H. pylori seropositive vaccine recipients, there were no significant associations between PGI, PGII and PGI:PGII levels and vibriocidal seroconversion. The enhanced seroconversion to oral cholera vaccine CVD 103-HgR among H. pylori seropositive African adults provides further evidence of the immunomodulating impact of H. pylori on oral vaccine immunogenicity.
Identifiants
pubmed: 33037244
doi: 10.1038/s41598-020-71754-9
pii: 10.1038/s41598-020-71754-9
pmc: PMC7547695
doi:
Substances chimiques
Cholera Vaccines
0
Immunoglobulin G
0
cholera vaccine CVD 103-HgR
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
16871Références
Bandyopadhyay, A. S., Garon, J., Seib, K. & Orenstein, W. A. Polio vaccination: past, present and future. Future Microbiol. 10, 791–808. https://doi.org/10.2217/fmb.15.19 (2015).
doi: 10.2217/fmb.15.19
pubmed: 25824845
Burnett, E., Jonesteller, C. L., Tate, J. E., Yen, C. & Parashar, U. D. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J. Infect. Dis. 215, 1666–1672. https://doi.org/10.1093/infdis/jix186 (2017).
doi: 10.1093/infdis/jix186
pubmed: 28430997
pmcid: 5543929
Levine, M. M. et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin. Infect. Dis. 45(Suppl 1), S24-28. https://doi.org/10.1086/518141 (2007).
doi: 10.1086/518141
pubmed: 17582564
Gauld, J. S., Hu, H., Klein, D. J. & Levine, M. M. Typhoid fever in Santiago, Chile: Insights from a mathematical model utilizing venerable archived data from a successful disease control program. PLoS Negl. Trop. Dis. 12, e0006759. https://doi.org/10.1371/journal.pntd.0006759 (2018).
doi: 10.1371/journal.pntd.0006759
pubmed: 30188904
pmcid: 6143279
Reyburn, R. et al. The case for reactive mass oral cholera vaccinations. PLoS Negl. Trop. Dis. 5, e952. https://doi.org/10.1371/journal.pntd.0000952 (2011).
doi: 10.1371/journal.pntd.0000952
pubmed: 21283614
pmcid: 3026767
Levine, M. M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 8, 129. https://doi.org/10.1186/1741-7007-8-129 (2010).
doi: 10.1186/1741-7007-8-129
pubmed: 20920375
pmcid: 2958895
Steele, A. D. et al. Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?. Hum. Vaccin. Immunother. https://doi.org/10.1080/21645515.2018.1553593 (2019).
doi: 10.1080/21645515.2018.1553593
pubmed: 30735087
pmcid: 6663148
Tacket, C. O. et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun. 67, 6341–6345 (1999).
doi: 10.1128/IAI.67.12.6341-6345.1999
Levine, M. M. et al. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev. Vaccines. 16, 197–213. https://doi.org/10.1080/14760584.2017.1291348 (2017).
doi: 10.1080/14760584.2017.1291348
pubmed: 28165831
Chen, W. H. et al. ingle-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin. Infect. Dis. 62, 1329–1335. https://doi.org/10.1093/cid/ciw145 (2016).
doi: 10.1093/cid/ciw145
pubmed: 27001804
pmcid: 4872293
Su-Arehawaratana, P. et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165, 1042–1048 (1992).
doi: 10.1093/infdis/165.6.1042
Suharyono, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340, 689–694 (1992).
doi: 10.1016/0140-6736(92)92231-4
Gotuzzo, E. et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61, 3994–3997 (1993).
doi: 10.1128/IAI.61.9.3994-3997.1993
Lagos, R. et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180, 1709–1712. https://doi.org/10.1086/315051 (1999).
doi: 10.1086/315051
pubmed: 10515838
Lagos, R. et al. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63, 707–709 (1995).
doi: 10.1128/IAI.63.2.707-709.1995
Cooper, P. J. et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 182, 1199–1206. https://doi.org/10.1086/315837 (2000).
doi: 10.1086/315837
pubmed: 10979918
Nomura, A. M. Y., Perez-Perez, G. I., Lee, J., Stemmermann, G. & Blaser, M. J. Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. Am J. Epidemiol. 155, 1054–1059 (2002).
doi: 10.1093/aje/155.11.1054
Blaser, M. J. et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 55, 2111–2115 (1995).
pubmed: 7743510
Suerbaum, S. & Michetti, P. Helicobacter pylori infection. N. Engl. J. Med. 347, 1175–1186. https://doi.org/10.1056/NEJMra020542347/15/1175[pii] (2002).
doi: 10.1056/NEJMra020542347/15/1175[pii]
pubmed: 12374879
Atherton, J. C. & Blaser, M. J. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J. Clin. Invest. 119, 2475–2487 (2009).
doi: 10.1172/JCI38605
Muhsen, K. et al. Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR. PLoS ONE ARTN e8399910.1371/journal.pone.0083999 (2014).
Muhsen, K., Pasetti, M. F., Reymann, M. K., Graham, D. Y. & Levine, M. M. Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive US adults with attenuated Salmonella Typhi oral vaccine CVD 908-htrA. J. Infect. Dis. 209, 1452–1458. https://doi.org/10.1093/infdis/jit625 (2014).
doi: 10.1093/infdis/jit625
pubmed: 24273182
Sow, S. O. et al. Randomized, placebo-controlled, double-blind phase 2 trial comparing the reactogenicity and immunogenicity of a single standard dose to those of a high dose of CVD 103-HgR live attenuated oral cholera vaccine, with Shanchol inactivated oral vaccine as an open-label immunologic comparator. Clin. Vaccine Immunol. 24, doi:UNSP e00265–1710.1128/CVI.00265–17 (2017).
Zhang, X. M., Li, J. X., Zhang, G. Y., Li, X. H. & Gu, H. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China. BMC Gastroenterol. 14, 3. https://doi.org/10.1186/1471-230X-14-3 (2014).
doi: 10.1186/1471-230X-14-3
pubmed: 24383519
pmcid: 3893538
Nardone, G. et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment. Pharmacol. Ther. 22, 1139–1146. https://doi.org/10.1111/j.1365-2036.2005.02734.x (2005).
doi: 10.1111/j.1365-2036.2005.02734.x
pubmed: 16305728
Samloff, I. M. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 61, 185–188 (1971).
doi: 10.1016/S0016-5085(19)33596-6
Samloff, I. M. & Liebman, W. M. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 65, 36–42 (1973).
doi: 10.1016/S0016-5085(19)33138-5
Miki, K. & Urita, Y. Using serum pepsinogens wisely in a clinical practice. J. Dig. Dis. 8, 8–14. https://doi.org/10.1111/j.1443-9573.2007.00278.x (2007).
doi: 10.1111/j.1443-9573.2007.00278.x
pubmed: 17261129
Kekki, M., Samloff, I. M., Varis, K. & Ihamaki, T. Serum pepsinogen I and serum gastrin in the 438 screening of severe atrophic corpus gastritis. Scand. J. Gastroenterol. 439–440, 109–116 (1991).
doi: 10.3109/00365529109103997
Cao, Q., Ran, Z. H. & Xiao, S. D. Screening of atrophic gastritis and gastric cancer by. J. Dig. Dis. 8, 15–22. https://doi.org/10.1111/j.1443-9573.2007.00271.x (2007).
doi: 10.1111/j.1443-9573.2007.00271.x
pubmed: 17261130
Graham, D. Y. et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin. Gastroenterol. Hepatol. 4, 306–314. https://doi.org/10.1016/j.cgh.2005.11.003 (2006).
doi: 10.1016/j.cgh.2005.11.003
pubmed: 16527693
Broutet, N. et al. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br. J. Cancer. 88, 1239–1247. https://doi.org/10.1038/sj.bjc.6600877 (2003).
doi: 10.1038/sj.bjc.6600877
pubmed: 12698190
pmcid: 2747577
Muhsen, K. et al. Prevalence and determinants of serological evidence of atrophic gastritis among Arab and Jewish residents of Jerusalem: a cross-sectional study. BMJ Open. 9, e024689. https://doi.org/10.1136/bmjopen-2018-024689 (2019).
doi: 10.1136/bmjopen-2018-024689
pubmed: 30700483
pmcid: 6352795
Kotloff, K. L. et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382, 209–222. https://doi.org/10.1016/S0140-6736(13)60844-2 (2013).
doi: 10.1016/S0140-6736(13)60844-2
pubmed: 23680352
Kotloff, K. L. et al. The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS). Lancet Glob. Health. 7, e568–e584. https://doi.org/10.1016/S2214-109X(19)30076-2 (2019).
doi: 10.1016/S2214-109X(19)30076-2
pubmed: 31000128
pmcid: 6484777
Livio, S. et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin. Infect. Dis. 59, 933–941. https://doi.org/10.1093/cid/ciu468 (2014).
doi: 10.1093/cid/ciu468
pubmed: 24958238
pmcid: 4166982
Cohen, D., Block, C., Green, M. S., Lowell, G. & Ofek, I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 27, 162–167 (1989).
doi: 10.1128/JCM.27.1.162-167.1989
McNutt, L. A., Wu, C., Xue, X. & Hafner, J. P. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am. J. Epidemiol. 157, 940–943. https://doi.org/10.1093/aje/kwg074 (2003).
doi: 10.1093/aje/kwg074
pubmed: 12746247
McCullagh, P. N (Chapman and Hall, J. Generalized linear models. Second edition. edn, 1983).
Spiegelman, D. & Hertzmark, E. Easy SAS calculations for risk or prevalence ratios and differences. Am. J. Epidemiol. 162, 199–200. https://doi.org/10.1093/aje/kwi188 (2005).
doi: 10.1093/aje/kwi188
pubmed: 15987728
Wang, X. T. et al. The correlation between histological gastritis staging—"OLGA/OLGIM’ and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China. Scand. J. Gastroenterol. 52, 822–827. https://doi.org/10.1080/00365521.2017.1315739 (2017).
doi: 10.1080/00365521.2017.1315739
pubmed: 28436254
Nam, J. H. et al. OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population. Helicobacter. 19, 81–89. https://doi.org/10.1111/hel.12112 (2014).
doi: 10.1111/hel.12112
pubmed: 24617667
Kuipers, E. J. et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 345, 1525–1528. https://doi.org/10.1016/S0140-6736(95)91084-0 (1995).
doi: 10.1016/S0140-6736(95)91084-0
pubmed: 7791437
Ganga-Zandzou, P. S. et al. Natural outcome of Helicobacter pylori infection in asymptomatic children: a two-year follow-up study. Pediatrics 104, 216–221 (1999).
doi: 10.1542/peds.104.2.216
Muhsen, K., Jurban, M., Goren, S. & Cohen, D. Incidence, age of acquisition and risk factors of Helicobacter pylori infection among Israeli Arab infants. J. Trop. Pediatr. 58, 208–213. https://doi.org/10.1093/tropej/fmr068 (2012).
doi: 10.1093/tropej/fmr068
pubmed: 21908868
Cover, T. L. & Blaser, M. J. Helicobacter pylori in health and disease. Gastroenterology 136, 1863–1873 (2009).
doi: 10.1053/j.gastro.2009.01.073
Smith, S., Fowora, M. & Pellicano, R. Infections with Helicobacter pylori and challenges encountered in Africa. World J. Gastroenterol. 25, 3183–3195. https://doi.org/10.3748/wjg.v25.i25.3183 (2019).
doi: 10.3748/wjg.v25.i25.3183
pubmed: 31333310
pmcid: 6626727
Holcombe, C. Helicobacter pylori: the African enigma. Gut 33, 429–431. https://doi.org/10.1136/gut.33.4.429 (1992).
doi: 10.1136/gut.33.4.429
pubmed: 1582581
pmcid: 1374052
Nalin, D. R. et al. Cholera, non-vibrio cholera, and stomach acid. Lancet 2, 856–859. https://doi.org/10.1016/s0140-6736(78)91568-4 (1978).
doi: 10.1016/s0140-6736(78)91568-4
pubmed: 81410
Giannella, R. A., Broitman, S. A. & Zamcheck, N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann. Intern. Med. 78, 271–276 (1973).
doi: 10.7326/0003-4819-78-2-271
Sack, G. H. Jr. et al. Gastric acidity in cholera and noncholera diarrhoea. Bull. World Health Organ. 47, 31–36 (1972).
pubmed: 4538903
pmcid: 2480805
Schiraldi, O., Benvestito, V., Di Bari, C., Moschetta, R. & Pastore, G. Gastric abnormalities in cholera: epidemiological and clinical considerations. Bull. World Health Organ. 51, 349–352 (1974).
pubmed: 4549488
pmcid: 2366304
Gitelson, S. Gastrectomy, achlorhydria and cholera. Isr. J. Med. Sci. 7, 663–667 (1971).
pubmed: 5560990
Clemens, J. et al. Impact of infection by Helicobacter pylori on the risk and severity of endemic cholera. J. Infect. Dis. 171, 1653–1656 (1995).
doi: 10.1093/infdis/171.6.1653
Leon-Barua, R. et al. Helicobacter pylori-associated chronic atrophic gastritis involving the gastric body and severe disease by Vibrio cholerae. Trans. R. Soc. Trop. Med. Hyg. 100, 567–572. https://doi.org/10.1016/j.trstmh.2005.09.013 (2006).
doi: 10.1016/j.trstmh.2005.09.013
pubmed: 16376396
Shahinian, M. L. et al. Helicobacter pylori and epidemic Vibrio cholerae O1 infection in Peru. Lancet 355, 377–378 (2000).
doi: 10.1016/S0140-6736(99)05143-0
Bhan, M. K. et al. Association between Helicobacter pylori infection and increased risk of typhoid fever. J. Infect. Dis. 186, 1857–1860 (2002).
doi: 10.1086/345762
Vollaard, A. M. et al. Helicobacter pylori infection and typhoid fever in Jakarta, Indonesia. Epidemiol. Infect. 134, 163–170. https://doi.org/10.1017/S0950268805004875 (2006).
doi: 10.1017/S0950268805004875
pubmed: 16409664
pmcid: 2870371
Mattsson, A., Lonroth, H., Quiding-Jarbrink, M. & Svennerholm, A. M. Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination. J. Clin. Invest. 102, 51–56. https://doi.org/10.1172/JCI22 (1998).
doi: 10.1172/JCI22
pubmed: 9649556
pmcid: 509064
Taye, B. et al. Association between infection with Helicobacter pylori and atopy in young Ethiopian children: A longitudinal study. Clin. Exp. Allergy. 47, 1299–1308. https://doi.org/10.1111/cea.12995 (2017).
doi: 10.1111/cea.12995
pubmed: 28787771
Cohen, D., Shoham, O., Orr, N. & Muhsen, K. An inverse and independent association between Helicobacter pylori infection and the incidence of shigellosis and other diarrheal diseases. Clin. Infec. Dis. 54, e35-42. https://doi.org/10.1093/cid/cir916 (2012).
doi: 10.1093/cid/cir916
Rothenbacher, D., Blaser, M. J., Bode, G. & Brenner, H. Inverse relationship between gastric colonization of Helicobacter pylori and diarrheal illnesses in children: results of a population-based cross-sectional study. J. Infect. Dis. 182, 1446–1449. https://doi.org/10.1086/315887 (2000).
doi: 10.1086/315887
pubmed: 11015236
Harris, V. et al. Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes. 9, 93–101. https://doi.org/10.1080/19490976.2017.1376162 (2018).
doi: 10.1080/19490976.2017.1376162
pubmed: 28891751
Harris, V. C. et al. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J. Infect. Dis. 215, 34–41. https://doi.org/10.1093/infdis/jiw518 (2017).
doi: 10.1093/infdis/jiw518
pubmed: 27803175
Harris, V. C. et al. Effect of antibiotic-mediated microbiome modulation on rotavirus vaccine immunogenicity: a human, randomized-control proof-of-Concept trial. Cell Host Microbe. 24, 197. https://doi.org/10.1016/j.chom.2018.07.005 (2018).
doi: 10.1016/j.chom.2018.07.005
pubmed: 30092197
Hooi, J. K. Y. et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153, 420–429. https://doi.org/10.1053/j.gastro.2017.04.022 (2017).
doi: 10.1053/j.gastro.2017.04.022
pubmed: 28456631
Maiga, M. et al. Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako. Mali. J. Breath Res. https://doi.org/10.1088/1752-7155/10/3/036012 (2016).
doi: 10.1088/1752-7155/10/3/036012
pubmed: 27532494